Finerenone

Breastfeeding

FDA APPROVAL DATE: 07/09/2021

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Amiodarone, CYP3A4 inducers, CYP3A4 inhibitors, Efavirenz, Erythromycin, Grapefruit Juice, Itraconazole


No available data in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.

More frequent serum potassium monitoring is advised in patients receiving concomitant therapy with drugs or supplements that increase serum potassium.

Our database has 3 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CARDIOVASCULAR.
ENDOCRINE/METABOLIC.


Page last updated 08/26/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top